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Abstract
Objective: Cardiovascular diseases (CVD) are a leading cause of mortality and disease burden. Preventative interventions to
augment the population-level adoption of health lifestyle behaviours that reduce CVD risk are a priority. Face-to-face
interventions afford individualisation and are effective for improving health-related behaviours and outcomes, but they are
costly and resource intensive. Electronic and mobile health (e- and mHealth) approaches aimed at modifying lifestyle risk
factors may be an effective and scalable approach to reach many individuals while preserving individualisation. This
systematic review aims to (a) determine the effectiveness of multifactorial e- and mHealth interventions on CVD risk
and on lifestyle-related cardiometabolic risk factors and self-management behaviours among adults without CVD; and
(b) describe the evidence on adverse events and on the cost-effectiveness of these interventions.
Methods: Methods were detailed prior to the start of the review in order to improve conduct and prevent inconsistent decision
making throughout the review. This protocol was prepared following the PRISMA-P 2015 statement. MEDLINE, CINAHL,
Embase, PsycINFO, Web of Science, Cochrane Public Health Group Specialised Register and CENTRAL electronic databases will
be searched between 1991 and September 2019. Eligibility criteria are: (a) population: community-dwelling adults; (b)
intervention/comparison: randomised controlled trials comparing e- or mHealth CVD risk preventative interventions with
usual care; and (c) outcomes: modifiable CVD risk factors. Selection of study reports will involve two authors independently
screening titles and abstracts, followed by a full-text review of potentially eligible reports. Two authors will independently
undertake data extraction and assess risk of bias. Where appropriate, meta-analysis of outcome data will be performed.
Discussion: This protocol describes the pre-specified methods for a systematic review that will provide quantitative and
narrative syntheses of current multifactorial e- and mHealth CVD preventative interventions. A systematic review and meta-
analysis will be conducted following the methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions
and reported according to PRISMA guidelines.
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Introduction
Description of the condition
Despite evidence showing preventative measures and
early intervention are wise investments in improving
health and well-being,1,2 cardiovascular disease (CVD)
is the leading cause of mortality and disease burden
globally, accounting for approximately 32% of all
deaths in 2017. The total number of deaths is estimated
at 17.8 million, with ischaemic heart disease and stroke
ranking in the top three causes of disability-adjusted life
years.3,4 Population-level preventative interventions
aimed at the adoption of healthier lifestyle behaviours
and CVD risk-factor management are a priority, since
appropriate self-management of modifiable risk factors
can reduce the risk of developing CVD.5,6 Participation
in face-to-face behaviour-change preventative interven-
tions affords individualisation and is modestly effective
at decreasing risk factor levels.7 However, face-to-face
approaches are unlikely to be a population-level
solution, given the resources needed and the difficulty
many individuals have in accessing such services.8,9
Description of the intervention
Electronic and mobile health (e- and mHealth, respec-
tively) approaches may be an effective and scalable
approach to reach many underserved individuals,
while also preserving the individualisation that contrib-
utes to the effectiveness of traditional face-to-face
interventions.10–14 Cochrane meta-analytical evidence
demonstrates beneficial impacts of e- and mHealth
interventions on individual CVD risk factors, such as
smoking cessation,15,16 alcohol intake,17 weight loss18
and type 2 diabetes.19 However, CVD incidence is typ-
ically determined by the co-existence of multiple mod-
ifiable risk factors.5 Accordingly, heart and cardiology
professional associations highlight the multifactorial
nature of CVD in their guidelines, recommending the
application of multifactorial CVD risk scores (i.e. risk
assessment tools20–22 such as Framingham23) to esti-
mate the likelihood of an individual experiencing a
CVD event. Moreover, these guidelines recommend
targeting multiple key modifiable risk factors – includ-
ing abnormal cholesterol, raised blood pressure, diabe-
tes, smoking, unhealthy diet, excessive alcohol,
abdominal obesity and insufficient physical activity –
for reducing CVD risk.24–26
How the intervention might work
Evidence suggests targeting modifiable risk factors can
reduce the global burden of CVD.27,28 ‘Making Every
Contact Count’29 for improving population health is
recommended, and evidence demonstrates brief
opportunistic behaviour-change counselling interven-
tions have positive effects, such as increasing physical
activity,30 improving dietary behaviours31 or increasing
attempts of smoking cessation.32 Yet, improvement in
cardiometabolic indices and sustaining recommended
lifestyle behaviour changes may require additional
intervention beyond single practitioner counselling ses-
sions.33,34 Moreover, time demands impact practi-
tioner’s ability to provide recommended preventive
services.35 E- and mHealth approaches capitalise on
the processing power and connectivity of digital tech-
nologies to mirror strategies used in traditional face-to-
face delivery modes and may even offer opportunities
to expand these to provide long-term self-management
support.
Why it is important to do this review
E- and mHealth lifestyle behaviour change research has
mostly produced interventions targeting a single behav-
iour or risk factor.36,37 Evidence has demonstrated the
beneficial impact of e- and mHealth interventions on
single risk factors for CVD, such as smoking cessa-
tion,4,5 alcohol intake,6 blood pressure,38 body compo-
sition18 or blood glucose.7
Systematic reviews have also examined the effective-
ness of e- and mHealth interventions on CVD out-
comes and risk factors.39 This review was broad,
included randomised controlled trials (RCTs) and
observational cohort studies, populations from both
primary and secondary prevention, as well as single
and multifactorial interventions. CVD outcomes (e.g.
adverse events, including myocardial infarction, stroke
or Framingham risk score) were reduced, and positive
effects were reported for some (e.g. weight) but not all
risk factors (e.g. cholesterol, blood pressure), but het-
erogeneity was high.39 Studies included were published
until early 2014 and considering the fast pace of change
of e- and mHealth interventions, an update is war-
ranted.40,41 Additionally, differences in risk factor
severity in individuals with/without CVD suggests find-
ings from that review may not be applicable to a pri-
mary prevention context. Therefore, available evidence
does not allow assessment of the effectiveness of mul-
tifactorial e- and mHealth interventions for CVD pri-
mary prevention. Moreover, data on adverse events
and cost-effectiveness of these interventions have not
been assessed.
Objectives
This systematic review aims to investigate the effective-
ness of multifactorial e- and mHealth interventions for
modifying lifestyle-related cardiometabolic risk factors
and self-management behaviours among adults
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without CVD. Secondary objectives are to describe the
evidence on the adverse events and cost-effectiveness of
these interventions.
Methods
We detailed our methods prior to the start of the review
in order to improve conduct and prevent inconsistent
decision making throughout the review processes.42,43
This manuscript was prepared following the Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P) 2015 statement.42
Criteria for considering studies for this review
Search methods for identifying study reports, eligibility
criteria and methods for data extraction, assessing risk
of bias and statistical analysis were pre-specified in
PROSPERO – International Prospective Register of
Systematic Reviews44 (#CRD42019128277).
Types of studies. Eligible studies are RCTs, including
individual or cluster randomisation, with parallel-
group design and of at least three months duration
of intervention (i.e. three months post commencement
of intervention or baseline assessment). A minimum
post-intervention follow-up period will not be required.
Context. Primary prevention; eHealth and mHealth
interventions that target the primary prevention of
CVD. Individuals would be recruited from the general
population and/or in primary-care settings (e.g. general
practice, family practice). Secondary prevention trials
that include participants with existent CVD will be
excluded.
Types of participants. We will include studies involving
free-living, outpatient, community-dwelling adults
aged 18 years or older without a previous history of
CVD. Study participants can be at increased risk of
CVD (i.e. 1 risk factors and/or prescribed medication
to manage 1 risk factors) but cannot have a prior
history of coronary artery disease/angina/myocardial
infarction/revascularisation, transient ischaemic
attack/stroke, peripheral vascular disease, chronic
kidney disease, heart failure or cardiac arrhythmia.
Examples of CVD risk factors are dyslipidaemia, high
blood pressure, overweight or obesity, smoking,
impaired glucose metabolism or diabetes; examples of
prescribed medication include drugs for blood pressure
and/or cholesterol and/or diabetes.
Pharmacological therapies commonly prescribed to
people with diabetes are associated with reduced risk of
CVD events45,46 and may therefore reduce the impact
of concurrent lifestyle interventions. However, the
effects of multifactorial diabetes lifestyle interventions
on modifiable CVD risk factors can reduce the need for
pharmacological therapy while also having a compara-
ble effect on CVD event risk.47 While outcomes in con-
trolled trials of diabetes lifestyle interventions will be
affected by medication use in each treatment group,
impaired glucose metabolism remains a key CVD risk
factor, and lifestyle interventions can play an impor-
tant role in CVD risk management. Therefore, trials
targeting diabetes cohorts will not be excluded from
this review if they satisfy remaining eligibility criteria.
Studies that focus on secondary prevention have
been reviewed previously48 and will be excluded.
Studies that recruited children and adolescents (i.e.
<18 years old) and patient populations with prevalent
CVD as defined above will be excluded. Studies that
recruited individuals with and without prevalent CVD
will be included only if results are reported separately
for primary prevention participants.
Types of interventions. Eligible interventions will be those
that use e- and mHealth to target the modification of
multiple lifestyle behaviours to improve quantitative
CVD risk score and/or modifiable risk factor profile
(i.e. primary objective was the primary prevention of
CVD). eHealth interventions are defined as those that
use information and communications technologies—
mainly the Internet—to improve health and health
care. mHealth interventions are defined as those that
use mobile devices—such as mobile phones, patient
monitoring devices, personal digital assistants and
other wireless devices—to support medical/public-
health practice.
Eligible lifestyle behaviours and CVD risk factors
will include smoking, diet, alcohol, physical activity,
sedentary behaviour, sleep, stress management, choles-
terol and glucose/HbA1c concentrations, blood pres-
sure and body composition/anthropometry.
The e/mHealth intervention can be supplemented
with other forms of delivery, but e/mHealth needs to
be the predominant mode of delivery/main component.
Similar criteria has been applied in previous reviews
due to difficulty in assessing impact of e/mHealth on
health outcomes when used as an adjunct to other
interventions.37 Studies that deliver interventions via
desktop or laptop computers but do not require an
Internet connection will be excluded.
We will exclude studies where interventions target a
single risk factor/self-care behaviour, those which
include a drug as the primary intervention (i.e. phar-
macological intervention is the main component) and
those where the sample includes individuals younger
than 18 years old.
Permitted comparison groups are inactive controls/
comparators, such as usual care, placebo, no
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intervention or waiting list. ‘Usual care’ CVD preven-
tative treatment is defined as no systematic provision of
e/mHealth CVD preventative treatment (i.e. primary
preventive treatments that are not received via e/
mHealth delivery models). Active control comparators
including any e/mHealth component, a different vari-
ant of e/mHealth, such as a different version of a web-
site/app, or a ‘less intensive’ intervention including e/
mHealth components will be excluded.
In summary, the following will be reasons to exclude
studies: non-random allocation, no multifactorial risk
factor intervention, no e/mHealth intervention, no rel-
evant CVD risk-factor changes measured and/or
reported, control group receiving substantial interven-
tion, no comparable control group identified, report
included participants younger than 18 years old,
report included CVD diagnosed participants, baseline
or post-intervention data not provided or post-
intervention data to at least three months was not
reported.
Types of outcome measures. Outcomes of interest will
include CVD risk scores and CVD risk factors as
either a primary or secondary outcome.
Primary outcomes. The primary outcome measure
will be multivariable CVD summary scores of risk
(e.g. Framingham, QRISK), assessed at baseline and
post intervention. Regarding timing of effect measures,
both short-term (i.e. measured immediately post inter-
vention) and long-term outcomes (i.e. measured at
longer-term follow-up) will be considered.
Congruency of measures and timing with protocols
(registries and/or published) will be checked.
Secondary outcomes. Secondary outcomes will
include:
• CVD risk factors:
• Cholesterol concentrations (e.g. total, low-density
lipoprotein, high-density lipoprotein,
triglycerides);
• Blood pressure (systolic and diastolic);
• Body composition (e.g. body mass index (BMI),
body fat percentage, waist and hip
circumference);
• Insulin resistance (e.g. fasting blood glucose,
HbA1c); and
• Cardiorespiratory fitness (e.g. VO2max).
• Health-related quality of life and/or health status
(e.g. physical function domain);
• Mental health–related outcomes (e.g. depression);
• Health-related behaviours:
• dietary intake;
• smoking;
• alcohol;
• physical activity;
• sedentary behaviour; and
• medication adherence.
• Adverse events, as defined by trial investigators,
such as physical or psychosocial events (e.g. anxiety)
and informed by the PRISMA harms checklist49;
and
• Cost-effectiveness and economic data.
Search methods for identification of studies
Electronic searches. The following electronic databases
will be searched between 6 August 1991 (World Wide
Web live/onset) and September 2019:
• Cochrane Central Register of Controlled Trials
(CENTRAL);
• Cochrane Public Health Group Specialised Register;
• PsycINFO (Ovid);
• MEDLINE (Ovid);
• EMBASE;
• CINAHL; and
• Web of Science.
The Cochrane sensitivity-maximising RCT filter for
MEDLINE will be applied. Following advice from a
medical librarian, a search strategy was developed for
MEDLINE and was adapted for other databases (see
Supplemental Material). Search terms will include med-
ical subject headings (MeSH) and keywords and are
based on previous Cochrane reviews.7,50 Searches will
be limited to human studies published in English.
Searching other resources. Electronic database searches
will be supplemented by hand searching reference lists
of included studies and relevant review articles identi-
fied by the search. Only original research articles will be
included. Non peer-reviewed search results (e.g.
reports, notes, abstracts, editorials, evaluations) will
be excluded. Conference abstracts and dissertations
are ineligible, but authors will be contacted to request
full-text peer-reviewed manuscripts.
We will further search the Interdisciplinary
Database: mHealth Evidence (https://www.mhealthevi
dence.org/) using combinations of the terms ‘cardiovas-
cular disease’ and ‘primary prevention’.
Data collection and analysis
Selection of studies. Two researchers (shared between A.
D., J.M. and R.D.) will independently assess eligibility
by screening the titles and abstracts of all records
retrieved. Potentially eligible studies will undergo full
4 DIGITAL HEALTH
text screening. We will record reasons for exclusion of
the ineligible studies. Duplicate reports will be identi-
fied and excluded. We will collate multiple reports of
the same study so that each study is the unit of analysis.
Covidence software (Melbourne, Australia) will be
used to assist with the screening and distribute the
review workload amongst the three researchers.51
Discrepancies will be discussed until reaching a consen-
sus or by involving the third researcher. If required,
study authors will be contacted up to twice for addi-
tional information to confirm eligibility.
Data extraction and management
Two researchers (shared between A.D., J.R. and R.D.)
will independently extract data from included study
reports into a data-extraction form designed for this
review. Cross-checks will be conducted computational-
ly for all quantitative data. Cross-checks for free-text
data will be conducted on 10% of included studies to
verify accuracy. Discrepancies will be resolved by dis-
cussion or, when necessary, by involving the third
researcher. Study authors will be contacted via email
up to twice for additional outcome data or trial details
when necessary (e.g. any missing required data or to
confirm data). Should standard deviations for out-
comes not be available, these will be imputed from
within study data according to methods outlined in
the Cochrane Handbook for Systematic Reviews of
Interventions (section 16.1.3 of Higgins52).
Data to be extracted from each included study
report will include:
• Eligibility (inclusion and exclusion criteria);
• Study design (e.g. number of arms, relevant arms,
level of randomisation – individual, cluster, block);
• Country, year, trial registration number;
• Participant characteristics (N, age mean, age
standard deviation (SD), age range, % male/
female, education, % white/ethnicity, BMI, baseline
CVD risk – described by group or altogether, as
provided);
• Intervention characteristics (e.g. duration, dose/
schedule, setting, type of technology/device –
mobile phone, smartphone, PDA –; media – appli-
cation software, MP3 audio, SMS, MMS, voice,
MP4 video –; comprehensiveness, individualisation,
N randomised, N completed, withdrawals);
• Comparator characteristics;
• Outcome characteristics (e.g. primary or secondary,
outcome variables, continuous/dichotomous, data
format – mean and SD or SE or 95% confidence
interval (CI), mean difference (MD) and p-value or
95% CI, odds ratio (OR) or risk ratio (RR) and
95% CI –, end point or change from baseline, time
points, units);
• Methodological quality (risk of bias domains); and
• Sources of funding.
A.D. will transfer data extracted into Review
Manager v5.3 (The Nordic Cochrane Centre,
Copenhagen, Denmark).
Assessment of risk of bias in included studies. Risk of bias
of each study will be assessed by two independent
researchers (shared between A.D., J.R. and J.M.)
using the Cochrane Collaboration tool.53 Sources of
bias assessed will be sequence generation, allocation
concealment, blinding of personnel and outcome asses-
sors (blinding of participants is impractical for
e/mHealth interventions), incomplete outcome data,
selective reporting and other potential threats to valid-
ity (e.g. baseline imbalance in cluster-randomised
trials). Risk of bias of cluster RCTs will consider
recruitment, baseline imbalances, loss of cluster or
incorrect analyses. Discrepancies will be resolved by
discussion or by involving the third researcher if nec-
essary. Treatment effects will be considered according
to risk of bias of each study that contributes to a
pooled outcome.
The GRADE framework will be used to assess the
quality of evidence for each outcome.54 Based on the
critical appraisal of risk of bias, evidence directness,
precision of effect estimates, heterogeneity and risk of
publication bias, evidence quality will be rated as high,
moderate, low or very low.
Measures of treatment effect. We anticipate effects of e-
and mHealth interventions will be analysed using a
series of random-effects model meta-analyses for each
modifiable CVD risk factor and behaviour. For contin-
uous outcomes (e.g. blood pressure, blood cholesterol)
measured on the same scale/instrument, we will use
MDs with 95% CIs to compare net differences (i.e.
intervention group minus comparison group).
Standardised MDs (SMDs) will be compared for out-
comes measured using different scales/instruments.
Outcome data extraction will source post-
intervention/end-point values where possible (i.e.
instead of change from baseline). We will not combine
post intervention/end point with change outcomes in
meta-analysis of SMDs, but we may consider combin-
ing studies reporting post intervention/end point with
studies reporting change from baseline when using
MDs (Cochrane Handbook for Systematic Reviews of
Interventions, section 9.4.5 of Deeks55). If necessary,
where meta-analysis will be inappropriate, studies
reporting outcome data as change from baseline will
be reported narratively. For dichotomous outcomes
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(e.g. smoking, clinical events), we will use OR or RR
with 95% CI.
Outcome data extraction will be sourced at both the
immediate post-intervention time point (i.e. short term;
outcome measured at the closest time to end of inter-
vention) and at the longest duration of follow up time
point that was reported in the primary study publica-
tion. For studies reporting both short- and long-term
outcomes, we plan to include the short-term outcome
data in the meta-analyses. We will consider pooling the
longest duration of follow-up reported in primary
reports, but the number of included studies reporting
long-term outcomes may be insufficient to consider
meta-analyses. We do not plan to use follow-up data
published in subsequent reports, as it is conceivable
that such long-term findings may reflect effects of co-
interventions, such as medication use.7
Where meta-analysis is not feasible (e.g. heterogene-
ity, insufficient studies to pool), a narrative synthesis
will be presented. We will summarise data narratively
and in tabular form.
Unit of analysis issues. This review may include RCTs
with parallel and cluster designs. We will extract data
on whether study investigators account for clustering in
their statistical analyses, such as a multilevel model or
generalised estimating equations. If analyses of includ-
ed studies are adjusted for clustering, then we plan to
meta-analyse individual RCTs with cluster RCTs.
Should cluster randomised trials not adjust for the clus-
tering effect in study reports, we will follow the meth-
ods outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (section 16.3 of Higgins52).
If a study has multiple intervention groups, we will
select the most relevant pair of arms and exclude the
others in order to avoid including a group of partici-
pants twice in the same meta-analysis. Pooling inter-
vention arms of interest into one group to obtain a
single pair comparison will be considered where appro-
priate (i.e. considering intervention arms’ characteris-
tics) according to the methods outlined in section 16.5
of Higgins.52
Dealing with missing data. We will follow the methods
outlined in section 16.1.3 of the Cochrane Handbook
for Systematic Reviews of Interventions to calculate
and impute missing statistics of interest, such as out-
come standard deviations (or change outcomes if this is
the outcome of interest and only baseline and post-
intervention/endpoint values are reported).52,55 We
will investigate attrition rates and losses to follow-up,
and appraise methods used by study investigators to
address missing data (e.g. imputation methods).
Assessment of heterogeneity. Heterogeneity will be tested
using the I2 and chi-square statistic for each outcome.
We may undertake fixed-effects model meta-analyses
where heterogeneity of effects is not substantial (i.e.
defined as I2 statistic <50%).55 We will investigate
potential reasons for heterogeneity by considering indi-
vidual study and subgroup characteristics.
Subgroup analysis. Depending on viability (e.g. number
of included studies55), we will undertake moderator/
subgroup analyses to assess potential effect modifiers.
Selection of subgroup characteristics will be informed
by effect modifiers previously identified in the literature
or motivated by clinically relevant hypotheses.
Subgroup analyses will be conducted as a means to
investigate heterogeneity and compare the magnitudes
of effect (rather than statistical significance).55 Pre-
specified potential subgroup analyses are:
• Intervention comprehensiveness (i.e. defined as
number of targeted risk factors). Based on evidence
indicating CVD, incidence is determined by the co-
existence of multiple modifiable risk factors and
importance of targeting the multifactorial risk pro-
file.20–22,36,56
• Mode of delivery. Studies of eHealth (e.g. web-
based) versus mHealth (e.g. SMS or smartphone
app or wearable sensors) versus combination of e-
and mHealth. Based on observational data suggest-
ing effects may differ according to mode of delivery
(e.g. web-based, telemedicine, SMS, email).39
• Co-intervention. Studies where the e/mHealth inter-
vention was stand-alone versus studies where inter-
ventions combine e/mHealth and non-digital
components (e.g. face-to-face sessions, behavioural
counselling). Based on evidence suggesting that e/
mHealth can be effective when delivered as stand-
alone interventions or combined with a non-digital
adjunct.57–62
• Intervention length. Studies where intervention was
up to three months versus longer than three months,
as the impact of intervention duration is unknown.
Alternatively, the median intervention duration will
be computed based on the included studies and used
as the cut-off value for subgroup analyses.
The following prognostic factors will also be consid-
ered for potential subgroup analyses:
• Co-morbidity. Studies among general populations
versus high-risk populations (i.e. diabetes or hyper-
tension or dyslipidaemia or obesity) versus high-risk
co-morbidity population (i.e. diabetes or hyperten-
sion or dyslipidaemia or obesity and one co-
morbidity). Based on evidence indicating effects
6 DIGITAL HEALTH
are beneficial in high-risk populations but negligible
in the general population.7
• Pharmacological intervention. Studies without phar-
macological treatment part of the intervention
versus including pharmacological treatment (e.g.
anti-hypertensives or cholesterol-lowering drugs or
smoking cessation medication). Based on evidence
suggesting a pharmacological intervention is a pos-
sible source of heterogeneity39 and on differential
effectiveness depending of outcome (e.g. coronary
heart disease mortality, stroke mortality, cholester-
ol, blood pressure).7,63
Sensitivity analysis. Robustness of pooled estimates from
random-effects models will be considered with sensitiv-
ity analyses. The ‘leave one out method’ will be used to
investigate the influence of individual studies on pooled
outcomes with considerable heterogeneity (i.e. defined
as I2 >50%). We will exclude studies judged to have a
high risk of bias from the meta-analysis of primary and
secondary outcomes.
Assessment of reporting biases. We will use funnel plots
to investigate publication bias for each outcome includ-
ing at least 10 studies.64
Discussion
This protocol describes the pre-specified methods for a
systematic review that will provide quantitative and
narrative syntheses of current evidence for the benefits,
risks and costs of multifactorial e- and mHealth CVD
preventative interventions. Deviations from this proto-
col and the future published review manuscript will be
reported in a section titled ‘Differences between proto-
col and review’. Findings from this review may high-
light opportunities for future development of CVD
primary prevention interventions and potentially sup-
port evidence-based decision making by health practi-
tioners and other decision makers working to
target CVD.
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